Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 8/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406078 | 0.82 | PTGDR2 (0.77) | PTGDR2AKR1B1LMNAMEN1POLB | |
| Ammonia Solution, Strong SCHEMBL5356478 | 0.81 | PTGDR2 (0.76) | PTGDR2AKR1B1LMNAMEN1POLB | |
| SCHEMBL1405983 | 0.70 | PTGDR2 (0.78) | PTGDR2AKR1B1LMNAMEN1POLB | |
| SCHEMBL1406103 | 0.68 | PTGDR2 (1.00) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1406093 | 0.68 | PTGDR2 (0.79) | PTGDR2AKR1B1LMNAMEN1POLB | |
| SCHEMBL1406212 | 0.67 | PTGDR2 (0.78) | PTGDR2AKR1B1LMNAMEN1POLB | |
| SCHEMBL671414 | 0.65 | ENPP2 (0.60) | PTGDR2AKR1B1LMNAMEN1POLB | |
| SCHEMBL672201 | 0.65 | PTGDR2 (0.60) | PTGDR2AKR1B1LMNAMEN1POLB | |
| SCHEMBL671172 | 0.64 | ENPP2 (0.71) | PTGDR2AKR1B1LMNAMEN1POLB | |
| SCHEMBL672156 | 0.62 | EDNRB (0.57) | PTGDR2AKR1B1LMNAMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166607-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2007-01-23 | — | — | US | disclosed |
| US-20050165055-A1 | Novel substituted indoles | ASTRAZENECA AB (SE) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165055-A1 | Novel substituted indoles | IDO1, IDO2, TPH1 | PTGDR2 426/4885AKR1B1 302/4885LMNA 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.